Optimisation of sunitinib therapy in metastatic renal cell carcinoma: adverse-event management

Motzer, 2006, Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma, J Clin Oncol, 24, 16, 10.1200/JCO.2005.02.2574

Motzer, 2006, Sunitinib in patients with metastatic renal cell carcinoma, JAMA, 295, 2516, 10.1001/jama.295.21.2516

Motzer, 2007, Sunitinib versus interferon alfa in metastatic renal-cell carcinoma, N Engl J Med, 356, 115, 10.1056/NEJMoa065044

Gore, 2007, Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded open access trial with subpopulation analysis, J Clin Oncol, 25, 5010, 10.1200/jco.2007.25.18_suppl.5010

SUTENT, Summary of Product Characteristics. January 2007. Pfizer Inc 2007.

Houk, 2007, Exposure- response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/pharmacodynamic (PKPD) approach, J Clin Oncol, 25, 5027, 10.1200/jco.2007.25.18_suppl.5027

2006

Sane, 2004, Angiogenic growth factors and hypertension, Angiogenesis, 7, 193, 10.1007/s10456-004-2699-3

Struijker Boudier, 1992, The microcirculation and hypertension, J Hypertens Suppl, 10, S147, 10.1097/00004872-199212000-00016

Veronese, 2006, Mechanisms of hypertension associated with BAY 43– 9006, J Clin Oncol, 24, 1363, 10.1200/JCO.2005.02.0503

Kollmannsberger, 2007, Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects, Can Urol Assoc J, 1, S41

Robert, 2005, Cutaneous side- effects of kinase inhibitors and blocking antibodies, Lancet Oncol, 6, 491, 10.1016/S1470-2045(05)70243-6

Webster-Gandy, 2007, Palmar-plantar erythrodysesthesia (PPE): A literature review with commentary on experience in a cancer centre, Eur J Oncol Nurs, 11, 238, 10.1016/j.ejon.2006.10.004

Rini, 2007, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, 99, 81, 10.1093/jnci/djk008

Feldman, 2007, Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib, J Natl Cancer Inst, 99, 974, 10.1093/jnci/djm006

de Castro, 2006, Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies), Curr Opin Oncol, 18, 307, 10.1097/01.cco.0000228733.55132.ea